Genetic variation in the endothelin system: Do polymorphisms affect the therapeutic strategies?

Annals of the New York Academy of Sciences

Volumn 1069, Issue , 2006, Pages 34-50

  Rossi, Gian Paolo ^a,b   Pitter, Gisella ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Cardiovascular disease; Cardiovascular system; Endothelin 1; G protein coupled receptors; Genetic polymorphisms

Indexed keywords

ALDOSTERONE; CHYMASE; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN RECEPTOR ANTAGONIST; G PROTEIN COUPLED RECEPTOR; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; METALLOPROTEINASE; NITRIC OXIDE; PROSTACYCLIN;

ALDOSTERONE RELEASE; ATHEROSCLEROSIS; AUTOCRINE EFFECT; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CELL MIGRATION; CELL PROLIFERATION; CONFERENCE PAPER; ECE 1 GENE; ENDOTHELIUM CELL; ET 1 GENE; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GLOMERULOSCLEROSIS; HEART FAILURE; HOMEOSTASIS; HUMAN; HYPERTENSION; IDIOPATHIC DISEASE; KIDNEY FAILURE; PROTEIN SECRETION; PULMONARY HYPERTENSION; RELIABILITY; RESTENOSIS; SCLERODERMA; SINGLE NUCLEOTIDE POLYMORPHISM; SYNTHESIS; VASOCONSTRICTION;

EID: 33745632032     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1351.004     Document Type: Conference Paper

References (76)

1. YANAGISAWA, M., H. KURIHARA, et al. 1988. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411-415.
2. ROSSI, G.P. & A.C. PESSINA. 2005. Endothelins: molecular mechanisms in hypertension and cardiovascular diseases. In Molecular Mechanisms of Hypertension. D. Di Pette, E.L. Schiffrin & J.H. Sowers, Eds.: XX.Taylor & Francis Medical Books. London.
3. ROSSI, G.P., S. COLONNA, et al. 1999. Endothelin-1 and its mRNA in the wall layers of human arteries Ex vivo. Circulation 99: 1147-1155.
4. RUBANYI, G.M. & M.A. POLOKOFF. 1994. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol. Rev. 46: 325-415.
5. ROSSI, G.P., G. ALBERTIN, et al. 1995. Expression of the endothelin-converting enzyme gene in human tissues. Biochem. Biophys. Res. Commun. 211: 249-253.
6. ALBERTIN, G., G.P. ROSSI, et al. 1996. Fine mapping of the human ECE gene by fluorescent in situ hybridization and radiation hybrids. Biochem. Biophys. Res. Commun. 221: 682-687.
7. YANAGISAWA, H., M. YANAGISAWA, et al. 1998. Dual genetic pathways of endothelin-mediated intercellular signaling revealed by targeted disruption of endothelin converting enzyme-1 gene. Development 125: 825-836.
8. URATA, H., A. KINOSHITA, et al. 1990. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J. Biol. Chem. 265: 22348-22357.
9. MAEDA, S., T. MIYAUCHI, et al. 1998. Prolonged exercise causes an increase in endothelin-1 production in the heart in rats. Am. J. Physiol. 275: H2105-H2112.
10. CORDER, R., J.A. DOUTHWAITE, et al. 2001. Endothelin-1 synthesis reduced by red wine. Nature 414: 863-864.
11. POLLOCK, D.M., T.L. KEITH, et al. 1995. Endothelin receptors and calcium signaling. FASEB J. 9: 1196-1204.
12. ROSSI, G., G. ALBERTIN, et al. 1994. Gene expression, localization, and characterization of endothelin A and B receptors in the human adrenal cortex. J. Clin. Invest. 94: 1226-1234.
13. TEERLINK, J.R.,V. BREU, et al. 1994. Potent vasoconstriction mediated by endothelin ETB receptors in canine coronary arteries. Circ. Res. 74: 105-114.
14. NUSSDORFER, G.G., G.P. Rossi, et al. 1999. Autocrine-paracrine endothelin system in the physiology and pathology of steroid-secreting tissues. Pharmacol. Rev. 51: 1-35.
15. LUSCHER, T.F. & M. BARTON. 2000. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 102: 2434-2440.
16. ROSSI, G.P., A. SACCHETTO, et al. 1999. Interactions between endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovasc. Res. 43: 300-307.
17. SCHIFFRIN, E.L. 2001. Role of endothelin-1 in hypertension and vascular disease. Am. J. Hypertens. 14: 83S-89S.
18. KRUM, H., R.J. VISKOPER, et al. 1998. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N. Engl. J. Med. 338: 784-790.
19. TADDEI, S., A. VIRDIS, et al. 1999. Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension. Circulation 100: 1680-1683.
20. ROSSI, G.P., C. GANZAROLI, et al. 2003. Endothelin receptor blockade lowers plasma aldosterone levels via different mechanisms in primary aldosteronism and high-to-normal renin hypertension. Cardiovasc. Res. 57: 277-283.
21. ORTH, S.R., J.P. ESSLINGER, et al. 1998. Nephroprotection of an ETA-receptor blocker (LU 135252) in salt-loaded uninephrectomized stroke-prone spontaneously hypertensive rats. Hypertension 31: 995-1001.
22. LERMAN, A., D.R. HOLMES, JR., et al. 1995. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation 92: 2426-2431.
23. LOPEZ FARRE, A., A. RIESCO, et al. 1993. Effect of endothelin-1 on neutrophil adhesion to endothelial cells and perfused heart. Circulation 88: 1166-1171.
24. KOWALA, M.C., P.M. ROSE, et al. 1995. Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol. Am. J. Pathol. 146: 819-826.
25. BEST, P.J.M., C.J. MCKENNA, et al. 1999. Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolemia. Circulation 99: 1747-1752.
26. BARTON, M., C.C. HAUDENSCHILD, et al. 1998. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc. Natl. Acad. Sci. USA 95: 14367-14372.
27. ZEIHER, A.M., H. GOEBEL, et al. 1995. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. Circulation 91: 941-947.
28. SALOMONE, O.A., P.M. ELLIOTT, et al. 1996. Plasma immunoreactive endothelin concentration correlates with severity of coronary artery disease in patients with stable angina pectoris and normal ventricular function. J. Am. Coll. Cardiol. 28: 14-19.
29. BLEZER, E.L.A., K. NICOLAY, et al. 1999. Early-onset but not late-onset endothelin-A-receptor blockade can modulate hypertension, cerebral edema, and proteinuria in stroke-prone hypertensive rats. Hypertension 33: 137-144.
30. OKADA, K., Y. NISHIDA, et al. 1998. Role of endogenous endothelin in the development of graft arteriosclerosis in rat cardiac allografts: antiproliferative effects of bosentan, a nonselective endothelin receptor antagonist. Circulation 97: 2346-2351.
31. SAKAI, S., T. MIYAUCHI, et al. 1996. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure: marked increase in endothelin-1 production in the failing heart. Circulation 93: 1214-1222.
32. KALUSKI, E., I. KOBRIN, et al. 2003. RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study. J. Am. Coll. Cardiol. 41: 204-210.
33. O'CONNOR, C.M., W.A. Gattis, et al. 2003. Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4). Am. Heart J. 145: S58-S59.
34. RICH, S. & V.V. MCLAUGHLIN. 2003. Endothelin receptor blockers in cardiovascular disease. Circulation 108: 2184-2190.
35. LOUIS, A.A., I.R. MANOUSOS, et al. 2002. Clinical trials update: the heart protection study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II and REMATCH. Impact of nicorandil on angina. Combination assessment of ranolazine in stable angina. Enhancing recovery in coronary heart disease patients. Assessment of cardioversion using transoesophageal echocardiography. azimilide post-infarct survival evaluation. Randomised evaluation of mechanical assistance for treatment of chronic heart failure. Eur. J. Heart Fail. 4: 111-116.
36. LUSCHER, T.F., F. ENSELEIT, et al. 2002. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation 106: 2666-2672.
37. DUPUIS, J., P. CERNACEK, et al. 1998. Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension. Am. Heart J. 135: 614-620.
38. GIAID, A., R.P. MICHEL, et al. 1993. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet 341: 1550-1554.
39. ZAMORA, M.A., E.C. DEMPSEY, et al. 1993. BQ123, an ETA receptor antagonist, inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells. Am. J. Respir. Cell. Mol. Biol. 9: 429-433.
40. WILLIAMSON, D.J., L.L. WALLMAN, et al. 2000. Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation 102: 411-418.
41. RUBIN, L.J., D.B. BADESCH, et al. 2002. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346: 896-903.
42. Available at: http://genecanvas.idf.inserm.fr/
43. BENJAFIELD, A.V., K. KATYK, et al. 2003. Association of EDNRA, but not WNK4 or FKBP1B, polymorphisms with essential hypertension. Clin. Genet. 64: 433-438.
44. BROWN, M.J., P. SHARMA, et al. 2000. Association between diastolic blood pressure and variants of the endothelin-1 and endothelin-2 genes. J. Cardiovasc. Pharmacol. 35: S41-S43.
45. CHARRON, P., F. TESSON, et al. 1999. Identification of a genetic risk factor for idiopathic dilated cardiomyopathy. Involvement of a polymorphism in the endothelin receptor type A gene. CARDIGENE group. Eur. Heart J. 20: 1587-1591.
46. DIEFENBACH, K., F.A. NAHAD, et al. 2004. Identification of twelve polymorphisms in the endothelin-1 gene by use of fluorescently labeled oligonucleotides and PCR with restriction fragment polymorphism analysis. Clin. Chem. 50: 448-451.
47. DONG, Y., X. WANG, et al. 2004. Endothelin-1 gene and progression of blood pressure and left ventricular mass: longitudinal findings in youth. Hypertension 44: 884-890.
48. FUNALOT, B., D. COURBON, et al. 2004. Genes encoding endothelin- converting enzyme-1 and endothelin-1 interact to influence blood pressure in women: the EVA study. J. Hypertens. 22: 739-743.
49. FUNKE-KAISER, H., F. REICHENBERGER, et al. 2003. Differential binding of transcription factor E2F-2 to the endothelin-converting enzyme-1b promoter affects blood pressure regulation. Hum. Mol. Genet. 12: 423-433.
50. GATH, R., A. GOESSLING, et al. 2001. Analysis of the RET, GDNF, EDN3, and EDNRB genes in patients with intestinal neuronal dysplasia and Hirschsprung disease. Gut 48: 671-675.
51. GORMLEY, K., S. BEVAN, et al. 2005. Polymorphisms in genes of the endothelin system and cerebral small-vessel disease. Stroke 36: 1656-1660.
52. GUMPRECHT, J., M.J. ZYCHMA, et al. 2000. Angiotensin I-converting enzyme gene insertion/deletion and angiotensinogen M235T polymorphisms: risk of chronic renal failure. End-Stage Renal Disease Study Group. Kidney Int. 58: 513-519.
53. GUMPRECHT, J., M. ZYCHMA, et al. 2002. Angiotensin I-converting enzyme and chymase gene polymorphisms - relationship to left ventricular mass in type 2 diabetes patients. Med. Sci. Monit. 8: CR603-CR606.
54. HE, H., L.M. LI, et al. 2005. A study of the relationships between angiotensin- converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril. Ann. Hum. Biol. 32: 30-43.
55. HERRMANN, S., K. SCHMIDT-PETERSEN, et al. 2001. A polymorphism in the endothelin-A receptor gene predicts survival in patients with idiopathic dilated cardiomyopathy. Eur. Heart J. 22: 1948-1953.
56. ISHIKAWA, K., T. FUNAYAMA, et al. 2005. Association between glaucoma and gene polymorphism of endothelin type A receptor. Mol. Vis. 11: 431-437.
57. KAETSU, A., T. KISHIMOTO, et al. 2004. The lack of relationship between an endothelin-1 gene polymorphism (Ala288ser) and incidence of hypertension: a retrospective cohort study among Japanese workers. J. Epidemiol. 14: 129-136.
58. NALOGOWSKA-GLOSNICKA, K., B.I. LACKA, et al. 2000. Angiotensin II type 1 receptor gene A1166C polymorphism is associated with the increased risk of pregnancy-induced hypertension. Med. Sci. Monit. 6: 523-529.
59. NICAUD, V., O. POIRIER, et al. 1999. Polymorphisms of the endothelin-A and -B receptor genes in relation to blood pressure and myocardial infarction: the Etude Cas-Temoins sur l'Infarctus du Myocarde (ECTIM) Study Am. J. Hypertens. 12: 304-310.
60. ORTLEPP, J.R., U. JANSSENS, et al. 2001. A chymase gene variant is associated with atherosclerosis in venous coronary artery bypass grafts. Coron. Artery Dis. 12: 493-497.
61. PFEUFER, A., K.J. OSTERZIEL, et al. 1996. Angiotensin-converting enzyme and heart chymase gene polymorphisms in hypertrophic cardiomyopathy. Am. J. Cardiol. 78: 362-364.
62. PINTO-SIETSMA, S.J., S.M. HERRMANN, et al. 2003. Role of the endothelin-1 gene locus for renal impairment in the general nondiabetic population. J. Am. Soc. Nephrol. 14: 2596-2602.
63. STEVENS, P.A. & M.J. BROWN. 1995. Genetic variability of the ET-1 and the ETA receptor genes in essential hypertension. J. Cardiovasc. Pharmacol. (26 Suppl.) 3: S9-S12.
64. TANAKA, C., K. KAMIDE, et al. 2004. Evaluation of the Lysl98Asn and -134delA genetic polymorphisms of the endothelin-1 gene. Hypertens. Res. 27: 367-371.
65. TIRET, L., O. POIRIER, et al. 1999. The Lys 198Asn polymorphism in the endothelin-1 gene is associated with blood pressure in overweight people. Hypertension 33: 1169-1174.
66. TZOURIO, C., M. EL AMRANI, et al. 2001. Association between migraine and endothelin type A receptor (ETA -231 A/G) gene polymorphism. Neurology 56: 1273-1277.
67. VASKU, A., L. SPINAROVA, et al. 2002. The double heterozygote of two endothelin-1 gene polymorphisms (G8002A and -3A/-4A) is related to big endothelin levels in chronic heart failure. Exp. Mol. Pathol. 73: 230-233.
68. VASKU, V., A. VASKU, et al. 2002. Genotype association of C(-735)T polymorphism in matrix metalloproteinase 2 gene with G(8002)A endothelin 1 gene with plaque psoriasis. Dermatology 204: 262-265.
69. WARPEHA, K.M., F. AH-FAT, et al. 1999. Dinucleotide repeat polymorphisms in EDN1 and NOS3 are not associated with severe diabetic retinopathy in type 1 or type 2 diabetes. Eye 13: 174-178.
70. ZAAHL, M.G., P.L. DU, et al. 2003. Significance of novel endothelin-B receptor gene polymorphisms in Hirschsprung's disease: predominance of a novel variant (561C/T) in patients with co-existing Down's syndrome. Mol. Cell. Probes. 17: 49-54.
71. ZEE, R.Y., V.S. RAO, et al. 1998. Three candidate genes and angiotensin-converting enzyme inhibitor-related cough: a pharmacogenetic analysis. Hypertension 31: 925-928.
72. ZYCHMA, M.J., E. ZUKOWSKA-SZCZECHOWSKA, et al. 2000. Angiotensinogen M235T and chymase gene CMA/B polymorphisms are not associated with nephropathy in type II diabetes Nephrol. Dial. Transplant. 15: 1965-1970.
73. HOSODA, K., R.E. HAMMER, et al. 1994. Targeted and natural (Piebald-lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice. Cell 79: 1267-1276.
74. PUFFENBERGER, E.G., K. HOSODA, et al. 1994. A missense mutation of the endothelin-B receptor gene in multigenic Hirschsprung's disease. Cell 79: 1257-1266.
75. TIRET, L. 2002. Gene-environment interaction: a central concept in multifactorial diseases. Proc. Nutr. Soc. 61: 457-463.
76. DEN DUNNEN, J.T. & S.E. ANTONARAKIS. 2001. Nomenclature for the description of human sequence variations. Hum. Genet. 109: 121-124.